Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Rein Therapeutics ( (RNTX) ) is now available.
On April 30, 2026, Rein Therapeutics announced it had priced an underwritten public offering of 50 million shares of common stock at $1.00 per share, for gross proceeds of $50 million, with a 45-day option for underwriters to buy up to an additional 7.5 million shares. The company plans to use the funds to fully finance its ongoing Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis, support working capital and general corporate purposes, and expects that, together with existing cash, this capital will fund operations into 2028, underscoring its near-term clinical and financing runway.
Also on April 30, 2026, Rein entered a letter agreement with Bios Partners entities, which agreed to defer conversion of 12,232 shares of Series X Non-Voting Convertible Preferred Stock and waive the requirement to reserve underlying common shares until the company increases its authorized stock. In return, Bios will receive warrants at the offering’s close to purchase 3 million common shares at $1.00 per share and has committed, with limited exceptions, not to sell or transfer the preferred or underlying shares until April 30, 2029, aligning a key investor with the company’s long-term capital structure.
The most recent analyst rating on (RNTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.
Spark’s Take on RNTX Stock
According to Spark, TipRanks’ AI Analyst, RNTX is a Neutral.
The score is weighed down primarily by weak financial fundamentals (no revenue, sustained losses, and ongoing cash burn with a shrinking equity base). Technicals also remain bearish with the stock below major moving averages, despite oversold signals. Valuation is difficult to support with a negative P/E and no dividend, while the recent private placement is a modest positive by helping fund operations.
To see Spark’s full report on RNTX stock, click here.
More about Rein Therapeutics
Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing first-in-class therapies for orphan pulmonary and fibrosis indications. Its lead candidate, LTI-03, is a synthetic peptide targeting alveolar epithelial cell survival and profibrotic signaling for idiopathic pulmonary fibrosis, while LTI-01 is a proenzyme for loculated pleural effusions, both holding Orphan Drug Designations in the U.S. and additional designations in the U.S. and E.U.
The company focuses on advancing this pipeline through mid-stage clinical development, targeting severe respiratory conditions with significant unmet need and leveraging regulatory incentives such as Orphan Drug and Fast Track status to accelerate development and potential market access.
Average Trading Volume: 324,554
Technical Sentiment Signal: Sell
Current Market Cap: $28.88M
For a thorough assessment of RNTX stock, go to TipRanks’ Stock Analysis page.